Table 6.
Evaluation results of the DNN model using 15 drugs with case reports.
| Drugs | CID | Endurance Levels |
Prediction | Prediction Probability |
|---|---|---|---|---|
| Flucloxacillin [26] | 21,319 | 6.7% | DILI-positive | 0.999 |
| Aliskiren [27] | 5,493,444 | 7.0% | DILI-positive | 0.999 |
| Rilpivirine [28] | 6,451,164 | 5.0% | DILI-positive | 0.994 |
| Escitalopram [29] | 146,570 | 5.0% | DILI-positive | 0.989 |
| Nilotinib [30] | 644,241 | 7.6% | DILI-positive | 0.982 |
| Olmesartan [31] | 158,781 | 6.3% | DILI-positive | 0.974 |
| Mesterolone [32] | 15,020 | 4.1% | DILI-positive | 0.971 |
| Levothyroxine [33] | 5819 | 3.9% | DILI-positive | 0.965 |
| Zanubrutinib [34] | 135,565,884 | 6.4% | DILI-positive | 0.922 |
| Phenprobamate [35] | 4770 | 2.8% | DILI-positive | 0.896 |
| Apixaban [36] | 10,182,969 | 5.5% | DILI-positive | 0.804 |
| Fasiglifam [37] | 24,857,286 | 7.0% | DILI-positive | 0.660 |
| Pirfenidone [38] | 40,632 | 2.6% | DILI-positive | 0.608 |
| Ligandrol [39] | 44,137,686 | 4.6% | DILI-negative | 0.378 |
| Ulipristal acetate [40] | 130,904 | 6.5% | DILI-negative | 0.036 |
DILI, drug-induced liver injury.